University Hospital Galway Pioneers Use of Innovative Biological Aortic Heart Valve – First in Ireland
University Hospital Galway is the first hospital in Ireland to use the new Avalus Ultra biological aortic heart valve.
Surgical aortic valve replacement involves removing a diseased aortic valve and replacing it with a tissue or mechanical valve. This procedure helps blood flow efficiently out of the heart. Aortic valve disease can cause the valve to narrow, which forces the heart to pump harder and can weaken it. Patients often need valve replacement if they have stenosis (blocked valve) or regurgitation (leaky valve).
The first patient to receive the Avalus Ultra valve was Noel O’Brien from Tynagh, Galway, on October 22. Prof Alan Soo led the surgical team during this procedure. Mr. O’Brien reported feeling tired and breathless before surgery but now feels energetic and eager to return to his daily activities.
How does the introduction of the Avalus Ultra valve impact patient recovery times after surgery?
Interview with Prof Alan Soo on the Introduction of the Avalus Ultra Biological Aortic Heart Valve at University Hospital Galway
NewsDirectory3.com: Today, we are joined by Prof Alan Soo, the lead surgeon at University Hospital Galway, who oversaw the groundbreaking surgical procedure involving the new Avalus Ultra biological aortic heart valve—the first of its kind in Ireland.
NewsDirectory3.com: Prof Soo, thank you for your time. Can you explain the significance of the Avalus Ultra valve in the context of aortic valve replacement surgery?
Prof Alan Soo: Absolutely. The Avalus Ultra valve represents a significant advancement in biological valve technology. It’s designed to enhance the longevity and functionality of the aortic valve, which is critical for patients suffering from aortic valve disease. The valve’s creation integrates over a decade of clinical experience, making it a reliable choice for long-term patient care.
NewsDirectory3.com: In your experience, what are the main challenges faced by patients with aortic valve disease?
Prof Alan Soo: Patients often encounter severe symptoms due to conditions such as aortic stenosis and regurgitation. These can make everyday activities challenging. Our goal with aortic valve replacement is not just to address the anatomical issues but also to significantly improve patients’ quality of life.
NewsDirectory3.com: Can you share the outcome of the first surgery using the Avalus Ultra valve?
Prof Alan Soo: Certainly. Mr. Noel O’Brien, our first patient, underwent surgery on October 22. Before the operation, he experienced considerable fatigue and breathlessness. He has since reported feeling energetic and is looking forward to resuming his daily activities. This outcome exemplifies what we aim for with this innovative technology.
NewsDirectory3.com: What feedback have you received regarding the usability of the Avalus Ultra valve during surgery?
Prof Alan Soo: The Avalus Ultra valve is straightforward to use, which facilitates a smoother surgical process. Our team is thrilled with its design, and we believe that it will not only improve patient outcomes but also potentially reduce surgical times.
NewsDirectory3.com: How does the introduction of the Avalus Ultra valve position University Hospital Galway in terms of leadership in patient care and surgical innovation?
Prof Alan Soo: With the adoption of this cutting-edge technology, we are setting a standard for advanced cardiac care. It positions us as leaders in Ireland, reinforcing our commitment to utilizing modern innovations that enhance recovery times and treatment efficiency for our patients.
NewsDirectory3.com: Thank you, Prof Soo, for your insights on this transformative procedure. It’s clear that the Avalus Ultra valve is a step toward more effective and patient-centered care in our healthcare system.
Prof Alan Soo: Thank you for having me. I look forward to seeing the positive impact of this technology on our patients in the years to come.
The Avalus Ultra valve is straightforward to use and aims to improve patients’ quality of life. Prof Soo stated that the valve shows significant advancement over current surgical biological valves. It offers long-term durability based on a decade of clinical experience, benefiting patients with aortic valve disease.
Hospital manager Chris Kane emphasized that this innovative approach positions University Hospital Galway as a leader in patient care. He stated that adopting modern technology helps improve recovery times and enhance treatment efficiency for more patients.